Lactococcus lactis strain Plasma

2 trials

Sponsors

Mizushima Daisuke, Mukae Hiroshi

Conditions

Human papilloma virus infection Human papilloma virus, Anal intraepithelial neoplasiacoronavirus disease 2019 (COVID-19) SARS-CoV-2

Unknown Phase

Active, not recruitingJPRN-jRCTs071210097

Mukae Hiroshicoronavirus disease 2019 (COVID-19) SARS-CoV-2

Start: 2022-01-07Target: 100Updated: 2026-06-29

Efficacy of Lactococcus lactis strain Plasma on clearance of anal HPV infection in men who have sex with men; multi-center, double-blinded, randomized placebo-controlled trial

RecruitingJPRN-jRCTs031220710

Mizushima DaisukeHuman papilloma virus infection Human papilloma virus, Anal intraepithelial neoplasia

Start: 2023-05-23Target: 150Updated: 2026-06-29

Related Papers

Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19: A Multicenter, Double-Blinded, Randomized-Controlled Trial (PLATEAU Study).

2025-10-25

552. Effect of <i>Lactococcus lactis strain plasma</i> (LC- Plasma) on immune response and symptoms in patients with mild COVID-19. Result of the multicenter, double- blinded, randomized controlled trial (PLATEAU study)

Open Forum Infectious Diseases2023-11-27

Efficacy of <i>Lactococcus lactis</i> strain plasma (LC-Plasma) in easing symptoms in patients with mild COVID-19: protocol for an exploratory, multicentre, double-blinded, randomised controlled trial (PLATEAU study)

BMJ Open2022-09-012 citations